Highest-materiality recent filing
Claritev Q2 revenue up 6.6% to $257.5M; raises FY2026 revenue and EBITDA guidance
Q2 2026 revenue $257.5M, +6.6% YoY; net loss narrowed to $59.2M from $62.6M.
Claritev DOJ criminal investigation closed; civil probe ongoing
DOJ notified Claritev on June 17, 2026, that the antitrust grand jury proceeding is closed and the company is not under criminal investigation.
Claritev confirms DOJ criminal antitrust probe, received grand jury subpoena in Aug 2024
DOJ Antitrust Division issued confidential grand jury subpoena in August 2024 regarding health insurance investigation.
Claritev Q1 revenue $244.7M (+5.8% YoY), net loss widens to $73.6M; updates FY guidance
Revenue $244.7M (+5.8% YoY); Adjusted EBITDA $146.9M (+3.4%), margin 60.0%.
Claritev Q4 revenue $246.6M (+6.2% YoY); FY 2025 revenue $965.4M; 2026 guidance and $75M buyback
Q4 2025 revenue $246.6M (+6.2% YoY); net loss narrowed to $80.6M from $138.0M; adjusted EBITDA $151.3M.
Hellman & Friedman affiliates sell 1.5M shares of Claritev at $51.50 in secondary offering
Affiliates of Hellman & Friedman sold 1,500,000 shares of Class A common stock at $51.50 per share.
Claritev Q3 revenue $246M (+6.7%), adj EBITDA $155.1M, raises FY guidance
Q3 revenue $246M (+6.7% YoY); net loss $69.8M vs $391.5M in Q3 2024.
Claritev renews contracts with top 10 clients, securing 70% of FY2024 revenue
Renewed all ten largest clients from FY2024; those clients contributed ~70% of total 2024 revenue.
Claritev reports Q2 2025 revenue up 3.5%, net loss narrows to $62.6M, raises full-year guidance
Revenue of $241.6M (+3.5% YoY); net loss of $62.6M vs $576.7M loss in Q2 2024.
Claritev Q1 revenue $231.3M (-1.4% YoY); net loss $71.3M vs $539.7M; reaffirms FY guidance
Revenue $231.3M, down 1.4% from $234.5M; net loss improved to $71.3M from $539.7M.
Claritev Q4 rev $232.1M (-4.9%), net loss $138M; FY net loss $1.65B; guidance rev -2% to flat
Q4 2024 revenue $232.1M, down 4.9% YoY; net loss $138.0M vs $31.4M loss a year ago.
MultiPlan completes $3.085B debt refinancing with new first lien notes and credit facilities
Issued $600M New 6.50% cash/5% PIK Second-Out A Notes due 2030 and $763M 5.75% Second-Out B Notes due 2030.
MultiPlan completes exchange offers with >99% participation, extends debt maturities
Over 99% participation across all four debt classes: 99.42% secured notes, 99.46% unsecured notes, 99.97% convertible notes, 99.38% term loans.
MultiPlan enters debt restructuring with ad hoc groups, extends maturities to 2029-2031
Transaction Support Agreement signed with ad hoc groups holding 72% of secured notes, 89% unsecured, 94% convertible, 60% term loans.
MultiPlan posts Q3 net loss $391.5M on $361.6M goodwill impairment; revenue down 5.1%
Revenue $230.5M (-5.1% YoY); net loss $391.5M vs loss $24.1M in Q3 2023.
MultiPlan stockholders approve reverse stock split; 1-for-40 split effective Sept. 20
Special meeting vote: 494,468,432 for, 5,160,539 against; proposal passed.
Q2 revenues $233.5M (-1.9% YoY); net loss $576.7M incl. $553.7M goodwill impairment.
MultiPlan CFO James Head to step down; Douglas Garis named successor effective Aug 5, 2024
Michael Attal resigns from Board effective Aug 1, tied to leaving Hellman & Friedman; no disagreement.
MultiPlan Q1 revenue $234.5M (-0.9% YoY); net loss $539.7M on $519.1M goodwill impairment
Revenue $234.5M vs $236.6M in Q1 2023, just below guided range due to $5-6M cyber incident impact.
MultiPlan receives NYSE deficiency notice for sub-$1.00 average stock price
Average closing price below $1.00 over 30 consecutive trading days ended March 27, 2024.
MultiPlan appoints Jerry Hogge as EVP and COO effective March 11, 2024
Hogge receives $500k base salary, 100% annual cash incentive target, 350% equity target.
MultiPlan Q4 rev $244.1M, net loss $31.4M; guides FY24 rev $1.0B-$1.03B
Q4 2023 revenue $244.1M (+1.3% YoY), net loss $31.4M (vs $650.1M loss), adjusted EBITDA $156.8M.
MultiPlan names Travis Dalton as CEO effective March 1, 2024; Dale White becomes Executive Chair
Travis Dalton to succeed Dale White as President and CEO on or around March 1, 2024; Dalton previously GM of Oracle Health.
MultiPlan Q3 2023 revenue $242.8M, net loss $24.1M; FY guidance tightened
Q3 2023 revenue $242.8M (-3.1% YoY); net loss $24.1M vs net income $19.7M in Q3 2022.
MultiPlan Q2 2023 revenue $238M (-18% YoY), net loss $36.4M, acquires BST
Q2 2023 revenue $238.0M, down 18% from $290.1M in Q2 2022; net loss $36.4M vs net income $13.5M.
Total consideration $160M: $140.8M cash + 21.6M shares of MPLN common stock; BST becomes wholly owned indirect subsidiary.
MultiPlan Q1 revenue down 21% YoY to $236.6M; net income falls 99.5% to $0.2M
Q1 2023 revenue $236.6M (down 20.6% YoY); net income $0.2M (down 99.5% YoY).
Effective as of the Effective Date, the Board appointed Ms. Jennifer Main to fill the newly created directorship, to serve as a Class II director and a member of the Audit Committee.
to fill the vacancy created by Mr. John Prince's passing
On September 14, 2026, the Board of Directors (the "Board") of Claritev Corporation (the "Company") appointed Mr. Ben Letham to the Board as a Class I director to fill the vacancy created by Mr. John Prince's passing, and appointed Mr. Letham to the Risk Committee of the Board, in each case effective September 14, 2026.
On September 6, 2024, Glenn R. August, a member of the Board of Directors (the “Board”) of MultiPlan Corporation (the “Company”), notified the Board that he was resigning from the Board (and its committees on which he serves) effective immediately.
On August 1, 2024, the Company and Mr. Garis entered into an employment agreement (the “Garis Employment Agreement”) providing for Mr. Garis’ appointment as Executive Vice President, Chief Financial Officer and Treasurer of the Company on the Transition Date.
On July 30, 2024, Michael K. Attal, a member of the Board of Directors (the “Board”) of MultiPlan Corporation (the “Company”), notified the Board that, in connection with the end of his employment with Hellman & Friedman, LLC, he was resigning from the Board (and its committees on which he serves) effective as of August 1, 2024.
On the Transition Date, Mr. Head will remain an employee of the Company and serve as a strategic advisor to the Board of Directors of the Company (the “Board”).
On May 7, 2024, Jeffrey A. Doctoroff, Executive Vice President, General Counsel and Corporate Secretary of MultiPlan Corporation (“MultiPlan” or the “Company”), provided the Company with notice of his resignation, effective on or about June 30, 2024.
On March 7, 2024, MultiPlan Corporation (the "Company" or "MultiPlan") issued a press release announcing the appointment of Jerry Hogge as Executive Vice President and Chief Operating Officer of the Company, effective March 11, 2024.
On the Transition Date, Mr. White will remain an employee of the Company and be appointed the Executive Chair of the Board.
Mark Tabak, the Company’s Non-Executive Chair of the Board, will step down from such role, effective as of the Transition Date.
Mr. Dalton will become the Company’s President and Chief Executive Officer succeeding Dale White on or around March 1, 2024.
Max materiality 0.90 · Median 0.60 · Most common event earnings